- 7/31/2007
- New Study Finds Tindamax® To Be Effective, Well-Tolerated Treatment for Bacterial Vaginosis Full Release»
- 5/24/2007
- FDA Approves Tindamax® for Bacterial Vaginosis First New Oral Treatment for Bacterial Vaginosis in a Decade Full Release»
- 11/13/2006
- Centers for Disease Control and Prevention Recommends Tindamax® for the Treatment of Trichomoniasis in Latest Sexually Transmitted Disease Guidelines Full Release»
- 8/17/2006
- Mission Pharmacal Submits Supplemental New Drug Application for Tindamax® (Tinidazole) as Treatment of Bacterial Vaginosis Full Release»
- 5/9/2006
- Most Common Curable STD a Significant Public Health Concern When Untreated, May Contribute to Spread of HIV New Web Resource Launched to Educate on Trichomoniasis Treatment Full Release»
- 5/8/2006
- Mission Pharmacal Completes Phase III Study of Tindamax® for the Treatment of Bacterial Vaginosis Full Release»
- 4/20/2006
- Mission Pharmacal Acquires Tindamax®: Treatment for Trichomoniasis, Most Common Non-Viral Sexually Transmitted Disease Potent, Well-Tolerated Therapy Allows Simple One-Day, One-Dose Regimen Full Release»
Only Tindamax® is approved to treat both bacterial vaginosis and trichomoniasis (TV).
Clinical Insight
Oral vs vaginal cream therapy: Patient preference for oral dosing is demonstrated to be 84%. More»
Beyond BV
Tindamax® may be prescribed for other infections including:
The Mission Pharmacal family of products
Learn more about innovative therapies including...
CitraNatal®Calcium citrate with vital nutrients for mother and baby » Ferralet® 90The iron therapy with biocomplementary absorption » Urocit®-KKidney stone therapy with wax-matrix delivery for slow, sustained release »
